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2010; Park et al, 2013). To our knowl-
edge, the present study is the ﬁrst to
demonstrate the importance of NAADP
as a Ca2+ signaling messenger in the
differentiation of keratinocytes. The
highly potent action of NAADP in
keratinocyte differentiation suggests
potential clinical applications for this
Ca2+ signaling molecule.
All animal studies were performed
according to a protocol approved by the
Institutional Animal Care and Use
Committee of the Chonbuk National
University Medical School.
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TO THE EDITOR
BRAF protein kinase is a crucial player
in melanoma, as it belongs to the highly
oncogenic RAS/RAF/MEK/ERK signaling
pathway (Matallanas et al., 2011), is
mutated in about 50% of melanoma
cases (Cantwell-Dorris et al., 2011), is
causally linked to melanomagenesis
(Dankort et al., 2009) and has recently
become a valuable therapeutic target
against metastatic melanoma (Menzies
and Long, 2014).
In the past years, the activity and
regulation of BRAF protein have been
studied extensively (Matallanas et al.,
2011). However, the regulation of BRAF
expression, which in principle is
equally important, has been largely ne-
glected. Here, we show that BRAF
mRNAs exist in at least two isoforms,
which differ in the length and sequence
of their 3′UTRs, and we discuss the
implications that this discovery may
have in terms of BRAF biology.
By performing 3′RACE in A375 mela-
noma cells, we obtained two most
abundant PCR fragments, which have
been cloned and sequenced (Figure 1a).
The A fragment corresponds to the 121 nt
long canonical (c) 3′UTR reported for
human BRAF in the most common data-
bases (Ensembl, ENST00000288602;
NCBI, NM_004333.4, polyA site at nt.
2442-47; Figure 1b, upper, Supplementary
Figure S1a and Supplementary Note S1
online). Conversely, the 1352nt long
fragment B corresponds to a BRAF tv
that so far has been only predicted
(XM_005250045.1 (BRAF tv X1), XM_
005250046.1 (BRAF tv X2), ENST0000
0496384). Interestingly, this BRAF tv,
which from now on we call X1, is trans-
cribed from an additional 19th exon
located ~8 kbp downstream of the last
canonical exon (the 18th) and is highly
conserved between humans, mouse,
and rat (Figure 1b, lower, Supplementary
Figure S1b and Supplementary Note S2
online).
In order to conﬁrm the results
obtained by 3′RACE, we used real-Accepted article preview online 16 February 2015; published online 12 March 2015
Abbreviations: ceRNA, competitive endogenous RNA; ORF, open reading frame; MRE, microRNA
recognition element; RNA-seq, RNA-sequencing; RBP, RNA binding protein; tv, transcript variant
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time PCR and measured the expression
levels of the c and the X1 isoforms in
melanocytes and in a wide panel of
melanoma cell lines (Figure 1c).
Because of the high similarity between
BRAF and its expressed pseudogene
BRAFP1 (Zou et al., 2009; Kalyana-
Sundaram et al., 2012), which spans the
entire coding sequence and extends
to the canonical 3′UTR, it was not
possible to design real-time primers that
are c speciﬁc (that is, not cross amplify-
ing the X1 isoform) and at the same time
BRAF speciﬁc (that is, not cross amplify-
ing BRAFP1, see Supplementary Figure
S2a,b online). Therefore, we cannot
exclude the fact that the PCR products
obtained using the c-speciﬁc primers
are derived from the ampliﬁcation of
both the canonical parental BRAF and
BRAFP1 (see Supplementary Note S3
online for further details). However, even
taking this technical limitation into
account, we still found that the X1
isoform is consistently more expressed
compared with the c isoform. This trend
is shared between normal melanocytes
and melanoma lines with different BRAF
and NRAS mutational status. Further-
more, a similar trend is observed in other
lineages (breast, cervix, colon, lung, and
prostate, Supplementary Figure S3
online).
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Figure 1. Identiﬁcation of BRAF 3′UTR isoforms. (a) 3′RACE performed on the cDNA derived from A375 melanoma cells produced two most abundant PCR
fragments (A and B). (b) Schematic representation of 3’RACE results. Fragment A corresponds to the canonical BRAF 3′UTR, which is 121nt long and is
transcribed from exon 18. Fragment B corresponds to the predicted X1 3′UTR, which is 1352 nt long and is transcribed from an additional exon 19. The
sequences of the two 3′UTRs are completely unrelated. The very last parts of the ORFs differ as well. White rectangles: coding sequences. Gray and black
rectangles: canonical 3’UTR and X1 3’UTR, respectively. Striped rectangle: X1-speciﬁc coding sequence. (c) Quantiﬁcation of the canonical and the X1 3′UTR by
real-time PCR. The bars represent the mean± s.e.m. of two independent experiments. (d) Coverage of the canonical 3′UTR, the X1 3′UTR, and the ORF of BRAF
in 78 melanoma samples (SKCM data set, The Cancer Genome Atlas).
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In order to unambiguously detect both
the c and the X1 isoforms, we ana-
lyzed the RNA-sequencing data of
78 melanoma samples that are avail-
able at The Cancer Genome Atlas (SKCM
data set). As reported in Figure 1d and
Supplementary Figure S4 online, we
conﬁrmed that the X1 isoform (black) is
more expressed compared with the c
isoform (gray). Furthermore, the compar-
ison of the expression level of BRAF ORF
(red) with that of the X1 3’UTR (black)
allowed us to infer that the X1 isoform
accounts indeed for the vast majority of
the BRAF molecules.
The ﬁnding that BRAF 3′UTR is not just
one but rather a mix of multiple tran-
scripts of different length and sequence
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Figure 2. 3′UTR-speciﬁc BRAF-targeting microRNAs. (a) Position of predicted microRNA recognition elements on the canonical (gray) and X1 (black) 3′UTRs.
(b) List of canonical and X1-predicted microRNAs. (c) Schematic representation of BRAF isoforms and of their implications for BRAF expression and function.
Alternative splicing produces two BRAF transcripts (canonical and X1) that vary in the very last part of the ORF and in the 3′UTR. The c- and X1-BRAF mRNAs
are expected to be implicated in distinct regulatory circuits at the post-transcriptional level. Analogously, the c- and X1-BRAF proteins are expected to
have both common and isoform-speciﬁc functions. The color gray refers to the canonical 3′UTR, whereas the black color refers to the X1 3′UTR. Rectangles:
BRAF coding sequence and 3′UTR; curved lines: BRAF-related ceRNAs; straight lines: BRAF-regulating microRNAs; solid ﬁgures: proteins; double red lines:
nuclear membrane.
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opens entirely new ﬁelds of investigation,
as it calls for a deeper analysis of the
regulation of BRAF expression and func-
tion at multiple levels.
First and foremost, as c and X1 BRAF
have completely unrelated 3′UTR
sequences, they are expected to be
regulated post-transcriptionally by dif-
ferent sets of RNA binding proteins and
microRNAs. In Figures 2a and b we
indeed report that the four microRNAs
predicted as c 3′UTR-targeting and the
12 microRNA families predicted as X1
3′UTR-targeting do not show any
overlap.
Along this line, it should also be
considered that different 3′UTRs, hence
different sets of bound microRNAs,
might imply the involvement of the
two BRAF isoforms in different compe-
titive endogenous RNA networks (Tay
et al., 2014). As mentioned above,
the 3′UTR of BRAFP1 pseudogene is
highly similar to the canonical 3’UTR
(Supplementary Figure S2b online).
Therefore, as far as the 3′UTR is
concerned, BRAFP1 is supposed to
function as a competitive endogenous
RNA only for c BRAF and not for X1
BRAF (Poliseno et al., 2010;
Supplementary Figure S2c online).
Aside from the 3′UTR sequence, also
the very last part of BRAF ORF is
different between the c and the X1
isoform (Supplementary Figure S5
online, AFPVH vs EFAAFK). Therefore,
those cells that express BRAF transcripts
that differ in their 3′UTRs, also express
BRAF proteins that differ in their C-term
domains, with all the implications that
this might have in terms of the kinase-
dependent and -independent activi-
ties of BRAF, as well as of its post-
translational regulation (Lee et al.,
2011; Matallanas et al., 2011; Chen
et al., 2012).
The alternative splicing of BRAF
exons is quite common. Depending on
the exons that are skipped, a kinase-
dead protein (Hirschi and Kolligs,
2013), a constitutively active protein
(Baitei et al., 2009), or a protein insen-
sitive to BRAF inhibitors (Poulikakos
et al., 2011) is translated. Our disco-
very of a 19th exon enhances the
relevance of alternative splicing, as it
implies that it might be used to regulate
not only the activity of BRAF protein,
but also the level of BRAF mRNA
isoforms (Figure 2c).
As a ﬁnal remark, we would like
to emphasize that an in-depth study of
the regulation of BRAF expression,
besides being relevant per se, could
also have important translational impli-
cations, as it could help improve the
current therapeutic approaches against
metastatic melanoma (Kwong and
Davies, 2014; Menzies and Long,
2014).
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